This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels (TNT)

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: May 16, 2006
Last updated: May 1, 2007
Last verified: May 2007
The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients with pre-existing CHD. Secondary objectives include the safety profile of this treatment strategy, its cost-effectiveness, effect on other atherosclerotic-related events and procedures, and total mortality.

Condition Intervention Phase
Cardiovascular Disease Cerebrovascular Accident Coronary Heart Disease Drug: Atorvastatin Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: The Effect Of LDL-Cholesterol, Lowering Beyond Currently Recommended Minimum Targets On Coronary Heart Disesse (CHD) Recurrence In Patients With Pre-Existing CHD

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • The primary outcome is the time to occurrence of a major
  • cardiovascular event, defined as the composite outcome of the
  • following clinical endpoints
  • CHD death
  • Non-fatal/Non-procedure related MI
  • Resuscitated cardiac arrest or fatal/non-fatal stroke

Secondary Outcome Measures:
  • The occurrence of the following clinical events
  • Major coronary event (CHD death, non fatal myocardial infarction or resuscitated cardiac arrest)
  • any coronary event (major coronary event or CABG
  • PTCA, other revascularization procedure, procedure-related myocardial infarction, or documented angina)
  • cerebrovascular event (fatal or non fatal stroke, TIA)
  • peripheral vascular disease; hospitalization with primary diagnosis' of CHF
  • any cardiovascular event (any of the above); and all-cause mortality.

Estimated Enrollment: 8600
Study Start Date: April 1998
Estimated Study Completion Date: August 2004

Ages Eligible for Study:   35 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Men and women age 35-75 who have evident CHD

Exclusion Criteria:

Known hypersensitivity to HMG CO-A reductase therapy, liver disease, evidence of secondary hyperlipidemia

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00327691

  Show 313 Study Locations
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00327691     History of Changes
Other Study ID Numbers: 0981-117
Study First Received: May 16, 2006
Last Updated: May 1, 2007

Keywords provided by Pfizer:
Major cardiovascular event
Major Coronary event

Additional relevant MeSH terms:
Cardiovascular Diseases
Heart Diseases
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Vascular Diseases
Arterial Occlusive Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Atorvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors processed this record on September 21, 2017